News & Views | Published:

Adenosine receptor crossroads in sickle cell disease

Nature Medicine volume 17, pages 3840 (2011) | Download Citation

Adenosine therapy for sickle cell disease has been proposed to improve blood flow, mediate cytoprotection and inhibit natural killer cell activity. Complicating this approach, adenosine signaling also induces hemoglobin S polymerization, promoting 'sickling', vasoocclusion, hemolysis and organ damage (pages 79–86).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & N. Engl. J. Med. 359, 2254–2265 (2008).

  2. 2.

    et al. Nat. Med. 8, 1383–1389 (2002).

  3. 3.

    , , & Nat. Rev. Drug Discov. 7, 759–770 (2008).

  4. 4.

    et al. J. Am. Coll. Cardiol. 34, 1711–1720 (1999).

  5. 5.

    et al. J. Hypertens. 14, 19–29 (1996).

  6. 6.

    & Blood 116, 5010–5020 (2010).

  7. 7.

    et al. Blood 114, 667–676 (2009).

  8. 8.

    et al. Nat. Med. 17, 79–86 (2011).

  9. 9.

    et al. J. Clin. Invest. 118, 1491–1501 (2008).

  10. 10.

    Clin. Immunol. Immunopathol. 76, S228–S232 (1995).

  11. 11.

    & J. Am. Coll. Cardiol. 47, 1236 (2006).

  12. 12.

    , , , & J. Am. Coll. Cardiol. 45, 1775–1780 (2005).

  13. 13.

    , & Acta Physiol. Scand. 129, 189–194 (1987).

Download references

Acknowledgements

I thank S. Tofovic and E. Jackson, University of Pittsburgh, for helpful comments and insights on adenosine biology.

Author information

Affiliations

  1. Mark T. Gladwin is chief of the Division of Pulmonary, Allergy and Critical Care Medicine and director of the Vascular Medicine Institute, University of Pittsburgh, Pennsylvania, USA

    • Mark T Gladwin

Authors

  1. Search for Mark T Gladwin in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Mark T Gladwin.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0111-38

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing